13 March 2019 - - US-based biotechnology company Flow Pharma Inc has forged a collaboration with Norwegian bioinformatics company OncoImmunity AS, the company said.

Under the agreement OncoImmunity will license the Immuneoprofilersoftware to Flow Pharma to support the clinical development and commercialisation of products based on the FlowVax platform.

The Immuneoprofiler has recently received the CE-IVD mark certification as a medical device, and fills some of the key gaps in neoantigen prediction.

The FlowVax vaccine platform developed by Flow Pharma, is optimized to simultaneously deliver multiple neoantigen peptide targets to enhance tumor-specific killer T-cell attack. 

OncoImmunity will develop a customised machine-learning layer, using clinical data generated by Flow Pharma, that will work-in-sync with the Immuneoprofiler software to make predictions tailored to the FlowVax platform.

OncoImmunity AS is a machine-learning company offering a proprietary technology to address key knowledge gaps in the prediction of bona fide immunogenic neoantigen for personalised cancer immunotherapy.

OncoImmunity's software facilitates effective patient selection for cancer immunotherapy and identifies neoantigen targets creating truly personalized cancer vaccines and cell therapies in clinically actionable time-frames.

Flow Pharma Inc. is a San Francisco Bay Area based, biotechnology company developing personalized neoantigen-based vaccines based on its proprietary FlowVax vaccine platform.

The FlowVax platform is optimized to simultaneously deliver multiple neoantigen peptide targets to enhance tumor-specific killer T-cell attack.

Each of the chemical components used in the FlowVax platform are currently part of an FDA approved vaccine or pharmaceutical, simplifying the regulatory pathway. Flow Pharma is now gearing up to test therapeutic cancer vaccines based on the FlowVax platform.

Each of the chemical components used in the FlowVax platform are currently part of an FDA approved vaccine or pharmaceutical, simplifying the regulatory pathway.

FlowVax vaccines can also be manufactured quickly and efficiently, keeping the cost down and getting the therapy in the hands of treating physicians soon after the diagnosis is made, for maximum efficacy.

However, as with all personalised vaccine approaches, the successful development and commercialisation of products based on the FlowVax platform is predicated on being able to identify clinically actionable and immunogenic neoantigen targets in a cost effective and clinically actionable time-frame.

OncoImmunity's Immuneoprofiler software, addresses this challenge, by harnessing the power of artificial intelligence to identify clinically relevant and immunogenic neoantigens from next generation sequencing data.